U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT07491328) titled 'Liquid Biopsy in Paraneoplastic Neurological Syndromes' on March 18.
Brief Summary: The main objective of the study is to assess whether circulating tumor cells (CTCs) can be detected in the peripheral blood of patients with paraneoplastic neurological syndromes (PNS) by diagnostic leukapheresis (DLA) combined with the CELLSEARCH(R) System during clinical routine workup. If CTCs can be identified, a detailed molecular genetic analysis will be performed to characterize mutations in oncogenes and tumor suppressor genes. In addition, the study aims to analyze cell-free DNA (cfDNA) in serum of patients.
Individuals with PNS and high- ...